EAMS scientific opinion: Avelumab in the treatment of bladder cancer
Study results show significant 7.1-month improvement in median overall survival with avelumab as first-line maintenance plus best supportive care (BSC) compared with BSC alone.
Join OnMedica and benefit from:
- Bitesize CPD and easy to digest content, free for UK-based GPs and specialist doctors
- High-quality, evidence-based content developed by expert editors and clinicians
- Articles, quizzes, videos, visual summaries and more
- Regulatory alerts and round-up of medical journals
- New content added daily, so you know you’re always up to date